Stage IIIB Skin Melanoma Terminated Phase 2 Trials for Aldesleukin (DB00041)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0029534 (Stage IIIB Skin Melanoma) | Terminated | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Treatment |